About this data
What it is
ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
Who files it
The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
How current
We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
Terms
ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
Worth knowing
A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
Not to be confused with
FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.

All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.

Studies updated per day, last 30 days

0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0
0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0

All industry-sponsored studies Sponsor matched to a public company

By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.

Latest clinical trial updates

Reset

Showing: ticker BIIB · All recent updates

Studies by the date their record was last updated.

Latest clinical trial updates
UpdatedStudySponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).EnrolledPrimary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.Source
Nov 13, 2026A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety in Participants Ag…
NCT07444476 · Spinal Muscular Atrophy
Salanersen
BIIB
Biogen
Phase 3Recruiting90Jun 23, 2028Registry ↗
Nov 12, 2026A Study to Learn About the Safety of BIIB147 and Its Effects in Adults With Amyotrophic Lateral Scl…
NCT07855211 · Amyotrophic Lateral Sclerosis
BIIB147, Placebo
BIIB
Biogen
Phase 1/2Recruiting69Jan 23, 2034Registry ↗
Nov 12, 2026A Study to Learn About The Effects of Felzartamab on Thyroid Function and Its Safety in Adults With…
NCT07722546 · Graves' Disease
Felzartamab, Placebo
BIIB
Biogen
Phase 2Recruiting60Jan 31, 2028Registry ↗
Nov 12, 2026A Study Utilising Data From European Union (EU) National Multiple Sclerosis (MS) Registries to Asse…
NCT05925049 · Multiple Sclerosis
Natalizumab
BIIB
Biogen
—Completed
was active, not recruiting
271Oct 29, 2026Registry ↗
Nov 12, 2026A Study to Learn How Nusinersen (Spinraza) Affects Participants With Spinal Muscular Atrophy (SMA)…
NCT05789758 · Muscular Atrophy, Spinal
No Intervention
BIIB
Biogen
—Recruiting20Oct 31, 2032Registry ↗
Nov 9, 2026A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary…
NCT06962800 · Primary Membranous Nephropathy
Felzartamab, Tacrolimus
BIIB
Biogen
Phase 3Recruiting180Jan 28, 2030Registry ↗
Nov 5, 2026A Study to Learn About the Effects of Felzartamab Infusions in Adults With Kidney Transplants Who H…
NCT07219043 · Microvascular Inflammation
Felzartamab, Placebo
BIIB
Biogen
Phase 2Recruiting81Feb 10, 2028Registry ↗
Nov 4, 2026Study to Learn If Tofersen (BIIB067) Can Delay ALS Symptoms and About Its Safety in Adults With a S…
NCT04856982 · Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene M…
Tofersen, Placebo
BIIB
Biogen
Phase 3Active, not recruiting158Aug 7, 2027Registry ↗
Nov 2, 2026A Study to Learn More About the Long-Term Safety and Effects of Felzartamab Infusions in Adults Wit…
NCT07444489 · Antibody-mediated Rejection, Microvascular Inflammation
Felzartamab
BIIB
Biogen
Phase 3Enrolling by invitation201Dec 31, 2031Registry ↗
Oct 30, 2026A Study to Learn About the Effect of Nusinersen (BIIB058) Given as Injections to Children With Spin…
NCT04488133 · Muscular Atrophy, Spinal
Nusinersen
BIIB
Biogen
Phase 4Completed46Oct 9, 2025Registry ↗
Oct 26, 2026A Study to Evaluate Long-Term Safety of Vumerity and Tecfidera in Participants With Multiple Sclero…
NCT05767736 · Multiple Sclerosis
Diroximel Fumarate, Dimethyl Fumarate
BIIB
Biogen
—Active, not recruiting10,500Dec 1, 2032Registry ↗
Oct 26, 2026A Study of the Safety of Nusinersen (Spinraza®) and Its Effects on Motor Function in Koreans Living…
NCT04317794 · Muscular Atrophy, Spinal
Nusinersen Sodium Injection
BIIB
Biogen
—Active, not recruiting74Feb 5, 2027Registry ↗
Oct 23, 2026A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety When Given Before…
NCT07221669 · Muscular Atrophy, Spinal
Salanersen
BIIB
Biogen
Phase 3Recruiting30Nov 28, 2028Registry ↗
Oct 23, 2026A Study to Learn About the Safety of BIIB115 Injections and How BIIB115 is Processed in the Bodies…
NCT05575011 · Healthy Volunteer, Muscular Atrophy, Spinal
BIIB115, BIIB115-Matching Placebo
BIIB
Biogen
Phase 1Active, not recruiting62Nov 14, 2031Registry ↗
Oct 23, 2026A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Part…
NCT05531565 · Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous L…
Litifilimab, Placebo
BIIB
Biogen
Phase 2/3Active, not recruiting450Oct 20, 2026Registry ↗
Oct 22, 2026A Study to Learn About the Effects of Felzartamab on the Kidneys of Adults With Immunoglobulin A Ne…
NCT07889362 · Immunoglobulin A Nephropathy
Felzartamab
BIIB
Biogen
Phase 2Not yet recruiting25Aug 13, 2028Registry ↗
Oct 21, 2026A Study to Learn More About Friedrich's Ataxia in People Living in the Gulf Cooperation Council (GC…
NCT07887828 · Friedreich's Ataxia
BIIB
Biogen
—Not yet recruiting40Jan 1, 2029Registry ↗
Oct 15, 2026A Study to Learn About the Safety and Effects of Salanersen (BIIB115) When Given to Babies With Spi…
NCT07444450 · Muscular Atrophy, Spinal
Salanersen, Sham Procedure
BIIB
Biogen
Phase 3Recruiting42Jul 27, 2029Registry ↗
Oct 15, 2026A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took i…
NCT05688436 · Multiple Sclerosis
Diroximel Fumarate, Alemtuzumab
BIIB
Biogen
—Active, not recruiting1,178Jan 17, 2031Registry ↗
Oct 14, 2026A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephrop…
NCT06935357 · Immunoglobulin A Nephropathy (IgAN)
Felzartamab, Placebo
BIIB
Biogen
Phase 3Recruiting454May 31, 2027Registry ↗
Oct 5, 2026A Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and it's Effec…
NCT05352919 · Systemic Lupus Erythematosus (SLE)
Litifilimab, Litifilimab-matching placebo
BIIB
Biogen
Phase 3Enrolling by invitation864May 3, 2032Registry ↗
Oct 2, 2026A Study to Learn More About the Effects and Long-Term Safety of Omaveloxolone (BIIB141) in Children…
NCT06953583 · Friedreich Ataxia
Omaveloxolone, Placebo
BIIB
Biogen
Phase 3Active, not recruiting255Nov 16, 2027Registry ↗
Sep 24, 2026A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pe…
NCT03958877 · Multiple Sclerosis, Relapsing-Remitting
BIIB017 (peginterferon beta-1a), Interferon beta type 1a
BIIB
Biogen
Phase 3Active, not recruiting152May 20, 2027Registry ↗
Sep 11, 2026Pediatric Spinal Muscular Atrophy (SMA) China Registry
NCT05042921 · Muscular Atrophy, Spinal
BIIB
Biogen
—Active, not recruiting600Sep 2, 2027Registry ↗
Sep 8, 2026A Long-Term Study of Patient-Reported Changes in Postpartum Depression Symptoms in People Starting…
NCT07398469 · Postpartum Depression
Zuranolone
BIIB
Biogen
—Recruiting300Mar 29, 2027Registry ↗
Sep 8, 2026A Study to Learn More About How Zuranolone Affects Postpartum Depression Symptoms in Participants W…
NCT07047820 · Depression, Postpartum
Zuranolone
BIIB
Biogen
—Completed305Aug 2, 2026Registry ↗
Sep 3, 2026A Study to Find Out How Nusinersen is Processed in the Body When Given Through the ThecaFlex DRx™ S…
NCT06555419 · Muscular Atrophy, Spinal
Nusinersen, ThecaFlex DRx System
BIIB
Biogen
Phase 1Recruiting78Sep 30, 2027Registry ↗
Sep 3, 2026A Study to Find Out How BIIB141 (Omaveloxolone) is Processed in the Body and to Learn More About It…
NCT06054893 · Friedreich Ataxia
Omaveloxolone
BIIB
Biogen
Phase 1Active, not recruiting33Jun 4, 2030Registry ↗
Sep 3, 2026A Study to Learn About the Effects and Safety of RTA 408 (Omaveloxolone) in People Aged 16 to 40 Wi…
NCT02255435 · Friedreich Ataxia
Omaveloxolone Capsules, 2.5 mg, Omaveloxolone Capsules, 5 mg
BIIB
Biogen
Phase 2Completed172Oct 31, 2019Registry ↗
Aug 13, 2026A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Chinese Participants With…
NCT07223723 · Amyotrophic Lateral Sclerosis
Tofersen
BIIB
Biogen
Phase 4Active, not recruiting12May 26, 2027Registry ↗
Aug 11, 2026Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate)
NCT05658497 · Multiple Sclerosis
Diroximel Fumarate, Avonex
BIIB
Biogen
—Recruiting908Jul 6, 2032Registry ↗
Aug 11, 2026A Study to Learn About the Long-Term Safety of Higher Doses of Nusinersen (BIIB058) Given as Inject…
NCT04729907 · Muscular Atrophy, Spinal
Nusinersen
BIIB
Biogen
Phase 3Completed115Jul 30, 2026Registry ↗
Aug 4, 2026A Long-Term Extension Study to Learn More About the Safety of Litifilimab (BIIB059) Injections and…
NCT06044337 · Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous L…
BIIB059 (litifilimab)
BIIB
Biogen
Phase 3Enrolling by invitation306Jun 26, 2029Registry ↗
Aug 4, 2026Adult Spinal Muscular Atrophy (SMA) China Registry
NCT05618379 · Muscular Atrophy, Spinal
BIIB
Biogen
—Active, not recruiting200Jun 1, 2028Registry ↗
Jul 27, 2026A Study to Learn More About the Safety of a Single Dose of BIIB144 and How it is Processed in the B…
NCT07662148 · Healthy Volunteer
BIIB144, Placebo
BIIB
Biogen
Phase 1Recruiting48Jun 19, 2028Registry ↗
Jul 10, 2026A Study to Learn How BIIB141 (Omaveloxolone) Affects the Health of Participants With Friedrich's At…
NCT06628687 · Friedreich Ataxia
Omaveloxolone
BIIB
Biogen
—Recruiting10Apr 30, 2035Registry ↗
Jul 10, 2026A Study to Determine the Biodistribution, Safety, and Tolerability of a Microdose of Radiolabeled D…
NCT06454721 · Healthy Volunteer
[89Zr]Zr-DFO-Diranersen, Diranersen
BIIB
Biogen
Phase 1Completed5Mar 5, 2026Registry ↗
Jun 30, 2026A Study to Learn About the Safety of Diranersen (BIIB080) Injections and Whether They Can Improve S…
NCT05399888 · Mild Cognitive Impairment Due to Alzheimer's Disease, Alzhe…
Diranersen, Diranersen-matching placebo
BIIB
Biogen
Phase 2Active, not recruiting416Mar 11, 2026Registry ↗
Jun 5, 2026A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Kidney T…
NCT06685757 · Antibody-mediated Rejection
Felzartamab, Placebo
BIIB
Biogen
Phase 3Active, not recruiting132Dec 1, 2026Registry ↗
Jun 4, 2026A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Ear…
NCT05348785 · Parkinson Disease
BIIB122, BIIB122-Matching Placebo
BIIB
Biogen
Phase 2Completed650Mar 9, 2026Registry ↗
May 26, 2026A Study to Find Out How Litifilimab is Processed in the Body in Healthy Participants When Given Und…
NCT06741657 · Healthy Volunteer
Litifilimab, AI
BIIB
Biogen
Phase 1Completed404Mar 10, 2026Registry ↗
May 22, 2026A Study to Learn About the Effect of Higher Doses of Nusinersen (BIIB058) Given as Injections to Pa…
NCT05067790 · Spinal Muscular Atrophy
Nusinersen
BIIB
Biogen
Phase 3Active, not recruiting45Sep 24, 2027Registry ↗
May 19, 2026Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Participants With Relapsing-Remitting Mul…
NCT02283853 · Relapsing-Remitting Multiple Sclerosis
dimethyl fumarate, Interferon β-1a
BIIB
Biogen
Phase 3Completed156Jul 8, 2025Registry ↗
May 14, 2026A Study to Learn How the Body Processes BIIB141 (Omaveloxolone) When Taken as a Capsule or as a Tab…
NCT07297199 · Healthy Volunteer
Omaveloxolone
BIIB
Biogen
Phase 1Completed70May 1, 2026Registry ↗
May 6, 2026A Study to Learn About the Safety of BIIB142 and How it is Processed in the Body of Healthy Adult P…
NCT07133828 · Healthy Volunteer
BIIB142, BIIB142-Matching Placebo
BIIB
Biogen
Phase 1Recruiting78Aug 6, 2026Registry ↗
Apr 28, 2026A Study to Learn More About the Long-Term Safety of BIIB141 (Omaveloxolone) in Participants With Fr…
NCT06623890 · Friedreich Ataxia
Omaveloxolone
BIIB
Biogen
—Recruiting300Oct 1, 2029Registry ↗
Apr 9, 2026A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Participants With Superox…
NCT07259980 · Amyotrophic Lateral Sclerosis
Tofersen
BIIB
Biogen
—Recruiting125Dec 30, 2033Registry ↗
Mar 19, 2026A Study to Learn About the Safety of Diroximel Fumarate (DRF) and Dimethyl Fumarate (DMF) and Their…
NCT07483632 · Relapsing Forms of Multiple Sclerosis
Diroximel Fumarate, Dimethyl Fumarate
BIIB
Biogen
Phase 3Not yet recruiting185Jul 28, 2034Registry ↗
Feb 20, 2026A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone…
NCT05798520 · Relapsing Forms of Multiple Sclerosis
BIIB091, DRF
BIIB
Biogen
Phase 2Completed127Feb 10, 2026Registry ↗
Feb 10, 2026A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve…
NCT04895241 · Lupus Erythematosus, Systemic
Litifilimab, Placebo
BIIB
Biogen
Phase 3Active, not recruiting548Sep 30, 2026Registry ↗

The newest 50 items, most recent first. Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 7:08 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances